RC48-ADC treatment for patients with HER2- expressing locally advanced or metastatic solid tumors: A real-world study
Số trang: 10
Loại file: pdf
Dung lượng: 1.03 MB
Lượt xem: 13
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
RC48-antibody-drug conjugates (ADC) link humanized anti-HER2 immunoglobulin with monomethyl auristatin E (MMAE). Clinical trials suggest promising antitumor activity in HER2-expressing solid tumors. This study probes RC48-ADC’s efficacy and safety in patients with HER2-expressing advanced or metastatic solid tumors.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Solid tumors Disease control rate Progression-free survival HER2-expressing advanced Metastatic solid tumor patientsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 88 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 37 0 0
-
11 trang 35 0 0
-
12 trang 34 0 0